OFF-LABEL USE OF ANTIBACTERIALS IN A CONTEXT OF ANTIMICROBIAL RESISTANCE THREAT
Objective: The objective of the study was to describe the off-label use of antibacterial in prescriptions for hospitalized adult patients as per the Brazilian drug regulatory agency, namely, the National Health Surveillance Agency (ANVISA).
Methods: This is a cross-sectional study with prescriptions for inpatients in a teaching hospital. Data collection and analysis were based on the checklist of the Medicine Prescription, Use and Administration Protocol of the Ministry of Health, where the off-label use is classified as per information of ANVISA’s Electronic Bulletin. Descriptive analyses were performed, and the method of logistic regression was used to evaluate the association between the off-label use of antibacterial and the explanatory variables age, gender, hospitalization clinic, and medical specialty.
Results: About one-third of the antibacterial was prescribed for off-label use, and the frequency of administration was the primary use outside standards established in the products’ licenses (87.3%), and dose (7.4%) and the administration route was next. The third-generation cephalosporin was the most consumed class in this regimen (69.5%). In some cases, the off-label use was not supported by scientific evidence. The off-label use was positively associated with the variables gender (odds ratio [OR] = 2.48; confidence interval [CI] = 1.23–4.92) and the prescribing clinic (OR = 4.94; CI = 2.61–8.96).
Conclusion: Off-label use is a frequent practice in the studied environment, and in the face of a dramatic scenario of increased antibacterial resistance, it is imperative to adopt measures for the standardization of records and the rational use of this class of drugs.
2. Davido B, Bouchand F, Calin R, Makhloufi S, Lagrange A, Senard O, et al. High rates of off-label use in antibiotic prescriptions in a context of dramatic resistance increase: A prospective study in a tertiary hospital. Int J Antimicrob Agents 2016;47:490-4.
3. Singh AP, Gupta U, Das S. Monitor the use of antibiotics in intensive care units with special focus on restricted antibiotics in tertiary care hospital of India. Asian J Pharm Clin Res 2016;9:256-9.
4. Paul N, Kumar SV. A comparative study on drug use of antimicrobial agents in medical and surgical intensive care units of a tertiary care hospital. Asian J Pharm Clin Res 2018;11:310-3.
5. Moody J, Cosgrove SE, Olmsted R, Septimus E, Aureden K, Oriola S, et al. Antimicrobial stewardship: A collaborative partnership between infection preventionists and healthcare epidemiologists. Infect Control Hosp Epidemiol 2012;33:328-30.
6. Mukattash TL, Hayajneh WA, Ibrahim SM, Ayoub A, Ayoub N, Jarab AS, et al. Prevalence and nature of off-label antibiotic prescribing for children in a tertiary setting: A descriptive study from Jordan. Pharm Pract (Granada) 2016;14:725.
7. Almalki ZS, Alahmari AK, Guo JJ, Cavanaugh TM. Off-label use of oral fluoroquinolone antibiotics in outpatient settings in the United States, 2006 to 2012. Pharmacoepidemiol Drug Saf 2016;25:1042-51.
8. Tansarli GS, Rafailidis PI, Kapaskelis A, Falagas ME. Frequency of the off-label use of antibiotics in clinical practice: A systematic review. Expert Rev Anti Infect Ther 2012;10:1383-92.
9. Pires AO, Ferreira MB, Nascimento KG, Felix MM, Pires PD, Barbosa MH, et al. Elaboration and validation of the medication prescription safety checklist. Rev Lat Am Enfermagem 2017;25:e2921.
10. Gonçalves MG, Heineck I. Frequency of prescriptions of off-label drugs and drugs not approved for pediatric use in primary health care in a Southern municipality of Brazil. Rev Paul Pediatr 2016;34:11-7.
11. Brasil. Agência Nacional de Vigilância Sanitária. Bulário Eletrônico. Available from: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.
12. Eguale T, Buckeridge DL, Verma A, Winslade NE, Benedetti A, Hanley JA, et al. Association of off-label drug use and adverse drug events in an adult population. JAMA Intern Med 2016;176:55-63.
13. Botelho SF, Martins MAP, Reis AMM. Analysis of new drugs registered in Brazil in view of the unified health system and the disease burden. Cien Saude Colet 2018;23:215-28.
14. Cabral LG, Meneses JP, Pinto PF, Furtado GH. Racionalização de antimicrobianos em ambiente hospitalar. Rev Soc Bras Clin Med 2018; 16:59-63.
15. Nery AA, Alves MS, Rios MA, Assunção PN, Filho AM. Perfil epidemiológico da morbimortalidade por causas externas em um hospital geral. J Nurs UFPE 2013;7:562-71.
16. Lat I, Micek S, Janzen J, Cohen H, Olsen K, Haas C, et al. Off-label medication use in adult critical care patients. J Crit Care 2011;26:89-94.
17. Eguale T, Buckeridge DL, Winslade NE, Benedetti A, Hanley JA, Tamblyn R, et al. Drug, patient, and physician characteristics associated with off-label prescribing in primary care. Arch Intern Med 2012; 172:781-8.
18. Andrade LJ, França LS, Melo PR, Araújo M. Off-label prescriptions in diabetic foot. J Vasc Bras 2014;13:192-7.
19. Drugdex Micromedex Healthcare Series. Thomson Reuters; 1974- 2011. Available from: http://www.periodicos.capes.gov.br.
20. Federico MP, Sakata RA, Pinto PF, Furtado GH. Noções sobre parâmetros farmacocinéticos/farmacodinâmicos e sua utilização na prática médica. Rev Soc Bras Clin Med 2017;15:201-5.
21. Joynt GM, Lipman J, Gomersall CD, Young RJ, Wong EL, Gin T, et al. The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients. J Antimicrob Chemother 2001;47:421-9.
22. Pericas JM, Cervera C, del Rio A, Moreno A, Garcia de la Maria C, Almela M, et al. Changes in the treatment of Enterococcus faecalis infective endocarditis in Spain in the last 15 years: From ampicillin plus gentamicin to ampicillin plus ceftriaxone. Clin Microbiol Infect 2014; 20:O1075-83.
23. United States of America. Food and Drug Administration. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/ label/2009/0550585s063lbl.pdf.
24. European Union. European Medicines Agengy. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_ document/Rocephin_30/WC500160113.pdf.
25. Makary MA, Daniel M. Medical error-the third leading cause of death in the US. BMJ 2016;353:i2139.
26. Watanabe JH, Mcinnis T, Hirsch JD. Cost of prescription drug-related. Morbidity and mortality. Ann Pharmacother 2018:52:1-9.
27. Chan JO, Baysari MT, Carland JE, Sandaradura I, Moran M, Day RO, et al. Barriers and facilitators of appropriate vancomycin use: Prescribing context is key. Eur J Clin Pharmacol 2018;74:1523-9.
28. Alamchandani RR, Khubchandani PR. A study evaluatingappropriateness of utilizationpattern of antimicrobials in patientsadmitted in medical intensive care unit of tertiary care teaching rural hospital. Int J Pharm Pharm Sci 2015;7:101-4.
29. Brasil. Ministério da Saúde. Agência Nacional de Vigilância Sanitária. Critérios Diagnósticos de Infecções Relacionada à Assistência à Saúde; 2013. Available from: http://www.portal.anvisa.gov.br/ documents/33852/3507912/Caderno+2+-+Crit%C3%A9rios+Diagn% C3%B3sticos+de+Infec%C3%A7%C3%A3o+Relacionada+%C3%A 0+Assist%C3%AAncia+%C3%A0+Sa%C3%BAde/7485b45a-074f- 4b34-8868-61f1e5724501.
30. Kala P, Rani RJ, Raja S. Prescription pattern of prophylactic antimicrobial agentsused in preoperativepatientsat a tertiary care teaching hospital. Int J Pharm Pharm Sci 2018;10:128-31.
31. Wijnakker R, Visser LE, Schippers EF, Visser LG, van Burgel ND, van Nieuwkoop C, et al. The impact of an infectious disease expert team on outpatient parenteral antimicrobial treatment in the Netherlands. Int J Clin Pharm 2019;41:49-55.
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.